Hyeon‐Seok Eom

4.0k total citations
133 papers, 1.7k citations indexed

About

Hyeon‐Seok Eom is a scholar working on Oncology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Hyeon‐Seok Eom has authored 133 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Oncology, 62 papers in Hematology and 52 papers in Pathology and Forensic Medicine. Recurrent topics in Hyeon‐Seok Eom's work include Lymphoma Diagnosis and Treatment (50 papers), Multiple Myeloma Research and Treatments (41 papers) and Protein Degradation and Inhibitors (22 papers). Hyeon‐Seok Eom is often cited by papers focused on Lymphoma Diagnosis and Treatment (50 papers), Multiple Myeloma Research and Treatments (41 papers) and Protein Degradation and Inhibitors (22 papers). Hyeon‐Seok Eom collaborates with scholars based in South Korea, United States and China. Hyeon‐Seok Eom's co-authors include Sun‐Young Kong, Cheolwon Suh, Hyewon Lee, Jin Seok Kim, Hye Jin Kang, Eunyoung Lee, Seok Jin Kim, Dok Hyun Yoon, Weon Seo Park and Won Seog Kim and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Hyeon‐Seok Eom

123 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hyeon‐Seok Eom South Korea 24 864 679 530 423 412 133 1.7k
Paolo F. Caimi United States 23 1.5k 1.7× 948 1.4× 320 0.6× 387 0.9× 467 1.1× 209 2.2k
Nilanjan Ghosh United States 28 1.4k 1.6× 939 1.4× 386 0.7× 701 1.7× 583 1.4× 160 2.4k
Nicola Di Renzo Italy 24 681 0.8× 944 1.4× 531 1.0× 275 0.7× 329 0.8× 98 1.9k
Kai Uwe Chow Germany 23 832 1.0× 866 1.3× 253 0.5× 389 0.9× 441 1.1× 57 1.9k
David Joske Australia 20 634 0.7× 774 1.1× 906 1.7× 400 0.9× 741 1.8× 45 2.6k
Carlos Panizo Spain 19 463 0.5× 538 0.8× 287 0.5× 276 0.7× 253 0.6× 93 1.5k
Amanda F. Cashen United States 29 1.0k 1.2× 1.4k 2.0× 891 1.7× 445 1.1× 629 1.5× 121 2.9k
Martin Wilhelm Germany 15 842 1.0× 1.3k 1.9× 260 0.5× 575 1.4× 344 0.8× 40 1.9k
Piers Blombery Australia 26 675 0.8× 606 0.9× 749 1.4× 653 1.5× 826 2.0× 122 2.4k
Leonard T. Heffner United States 21 784 0.9× 464 0.7× 996 1.9× 227 0.5× 856 2.1× 86 1.8k

Countries citing papers authored by Hyeon‐Seok Eom

Since Specialization
Citations

This map shows the geographic impact of Hyeon‐Seok Eom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hyeon‐Seok Eom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hyeon‐Seok Eom more than expected).

Fields of papers citing papers by Hyeon‐Seok Eom

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hyeon‐Seok Eom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hyeon‐Seok Eom. The network helps show where Hyeon‐Seok Eom may publish in the future.

Co-authorship network of co-authors of Hyeon‐Seok Eom

This figure shows the co-authorship network connecting the top 25 collaborators of Hyeon‐Seok Eom. A scholar is included among the top collaborators of Hyeon‐Seok Eom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hyeon‐Seok Eom. Hyeon‐Seok Eom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Choi, Yoon Seok, Joonho Shim, Ka‐Won Kang, et al.. (2024). Assessing the Efficacy of Bortezomib and Dexamethasone for Induction and Maintenance Therapy in Relapsed/Refractory Cutaneous T-Cell Lymphoma: A Phase II CISL1701/BIC Study. Cancer Research and Treatment. 57(1). 267–279. 1 indexed citations
3.
Jung, Sung‐Hoon, Je‐Jung Lee, Young Rok, et al.. (2024). Comparative analysis of single versus tandem autologous stem cell transplantation in patients with multiple myeloma in Korea: the KMM2102 study. Scientific Reports. 14(1). 24325–24325.
4.
Singh, Rohit Kumar, Young Ho Kim, Sang-Jin Lee, Hyeon‐Seok Eom, & Beom K. Choi. (2024). 4-1BB immunotherapy: advances and hurdles. Experimental & Molecular Medicine. 56(1). 32–39. 33 indexed citations
5.
Kim, Mihee, Je‐Jung Lee, Chang‐Ki Min, et al.. (2023). Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015). Annals of Hematology. 102(8). 2233–2240. 1 indexed citations
6.
Baek, Dong Won, Han‐Seung Park, Sang Kyun Sohn, et al.. (2023). Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study. The Korean Journal of Internal Medicine. 38(5). 734–746. 5 indexed citations
7.
Lee, Eunyoung, Youngil Koh, Junshik Hong, Hyeon‐Seok Eom, & Sung‐Soo Yoon. (2021). Recent Clinical Update of Acute Myeloid Leukemia: Focus on Epigenetic Therapies. Journal of Korean Medical Science. 36(13). e85–e85. 7 indexed citations
8.
Chung, Yousun, Hyoeun Shim, Dong-Eun Lee, et al.. (2020). Development of an Automated Image Analyzer for Microvessel Density Measurement in Bone Marrow Biopsies. Annals of Laboratory Medicine. 40(4). 312–316. 2 indexed citations
9.
Jung, Sung‐Hoon, Je‐Jung Lee, Jin Seok Kim, et al.. (2018). Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150). Biology of Blood and Marrow Transplantation. 24(5). 923–929. 7 indexed citations
10.
Lee, Hyewon, Weon Seo Park, Sang Hyun Hwang, et al.. (2017). A Case of Disseminated Infection with Skin Manifestation due to Non-neoformans and Non-gattiiCryptococcus in a Patient with Refractory Acute Myeloid Leukemia. Infection and Chemotherapy. 49(2). 142–142. 9 indexed citations
11.
Lee, Ki Hong, Kyong‐Ah Yoon, Eunyoung Lee, et al.. (2017). Chromothripsis in Treatment Resistance in Multiple Myeloma. Genomics & Informatics. 15(3). 87–97. 15 indexed citations
12.
Kim, Seung Ju, Jin Sung Kim, Dok Hyun Yoon, et al.. (2016). A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas. Annals of Oncology. 27(4). 712–718. 39 indexed citations
13.
Offner, Fritz, Olga Samoilova, Evgenii A. Osmanov, et al.. (2015). Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood. 126(16). 1893–1901. 98 indexed citations
14.
15.
16.
17.
Shin, Dong Wook, Jaeyong Cho, Debra Roter, et al.. (2014). Attitudinal concordance toward uptake and disclosure of genetic testing for cancer susceptibility in patient–family member dyads. Clinical Genetics. 86(2). 112–120. 2 indexed citations
18.
Kim, Seok Jin, Deok‐Hwan Yang, Jin Seok Kim, et al.. (2014). Concurrent chemoradiotherapy followed by l-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study. Annals of Hematology. 93(11). 1895–1901. 99 indexed citations
19.
Suh, Cheolwon, Daniel Lee, Chang‐Ki Min, et al.. (2010). Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients. Annals of Oncology. 22(2). 411–416. 25 indexed citations
20.
Eom, Hyeon‐Seok, et al.. (2003). A Case of Hyperammonemic Encephalopathy with Serum Amino Acid Alteration in Multiple Myeloma. Blood Research. 38(1). 64–67.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paolo F. Caimi Breakdown of academic impact, for papers by Nilanjan Ghosh Breakdown of academic impact, for papers by Nicola Di Renzo Breakdown of academic impact, for papers by Kai Uwe Chow Breakdown of academic impact, for papers by David Joske Breakdown of academic impact, for papers by Carlos Panizo Breakdown of academic impact, for papers by Amanda F. Cashen Breakdown of academic impact, for papers by Martin Wilhelm Breakdown of academic impact, for papers by Piers Blombery Breakdown of academic impact, for papers by Leonard T. Heffner
Rankless by CCL
2026